Watanidipine. AE 0047, Calbren, GJ 0956, Vatanidipine.
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004095:Dihydropyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008569:Memory Disorders / Q000188:drug therapy; D017202:Myocardial Ischemia / Q000188:drug therapy; D051381:Rats
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C064970:AE0047